Genmab — Marts 2017
-
Omtalen hos Sgen: http://www.seattlegenetics.com/SEA-CD40
-
Bulder det ved jeg ikke med sikkerhed, men et optimalt designet ADC stof vil både have effekt fra antistoffet og toxinet - og hvis jeg ikke husker helt forkert, så var tisotumab valgt som klinisk kandidat før det blev et ADC stof, så der vil ganske givet være effekt af begge dele. Mon ikke der ligger en artikel eller to på Genmabs hjemmeside omkring prækliniske data.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
